相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Identification of Potential Serum Biomarkers of Glioblastoma: Serum Osteopontin Levels Correlate with Poor Prognosis
Peddagangannagari Sreekanthreddy et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2010)
Grade-Specific Expression of Insulin-like Growth Factor-Binding Proteins-2,-3, and-5 in Astrocytomas: IGFBP-3 Emerges as a Strong Predictor of Survival in Patients with Newly Diagnosed Glioblastoma
Vani Santosh et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2010)
Genetic Screen Identifies Insulin-like Growth Factor Binding Protein 5 as a Modulator of Tamoxifen Resistance in Breast Cancer
Bo Young Ahn et al.
CANCER RESEARCH (2010)
Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines
Bhaswati Sarcar et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment
Yongping Crawford et al.
CANCER CELL (2009)
Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
Evanthia Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma
Andrew D. Norden et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Antiangiogenic therapies for high-grade glioma
Andrew D. Norden et al.
NATURE REVIEWS NEUROLOGY (2009)
Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas
Yi Lin et al.
NEURO-ONCOLOGY (2009)
IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas
Lynette M. Moore et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Platelet-Derived Growth Factor-Receptor α Strongly Inhibits Melanoma Growth In Vitro and In Vivo
Debora Faraone et al.
NEOPLASIA (2009)
Insulin-like growth factor-binding protein-5 (IGFBP-5) acts as a tumor suppressor by inhibiting angiogenesis
Seung Bae Rho et al.
CARCINOGENESIS (2008)
A role for VEGF as a negative regulator of pericyte function and vessel maturation
Joshua I. Greenberg et al.
NATURE (2008)
Malignant gliomas in adults
Patrick Y. Wen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
James J. Vredenburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Insulin-like growth factor binding protein 2 promotes glioma development and progression
Sarah M. Dunlap et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K-Akt pathway activation in glioblastoma and prostate cancer
R. Mehrian-Shai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer
Graeme Walker et al.
CLINICAL CANCER RESEARCH (2007)
Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma
Liliana Soroceanu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
A perivascular niche for brain tumor stem cells
Christopher Calabrese et al.
CANCER CELL (2007)
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL)
Madeleine Duvic et al.
BLOOD (2007)
Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589
DZ Qian et al.
CLINICAL CANCER RESEARCH (2006)
In vivo synergy between topoisomerase II and histone deacetylase inhibitors:: predictive correlates
DC Marchion et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas
Y Shikada et al.
CANCER RESEARCH (2005)
It's about time: Scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells
RL Bevins et al.
CANCER RESEARCH (2005)
Valproic acid alters chromatin structure by regulation of chromatin modulation proteins
DC Marchion et al.
CANCER RESEARCH (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584
DZ Qian et al.
CANCER RESEARCH (2004)
VEGF-null cells require PDGFR α signaling-mediated stromal fibroblast recruitment for tumorigenesis
JY Dong et al.
EMBO JOURNAL (2004)
Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis
AH Shih et al.
CANCER RESEARCH (2004)
Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs
IF Dunn et al.
JOURNAL OF NEURO-ONCOLOGY (2000)
分享论文
